Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AuspiCiOus-dMMR
NL-OMON52108Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab, capecitabine and oxaliplatin in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in interferon gamma expression signature and Change in cytotoxic T-cell infiltration. Started Nov 2021; status: recruiting.
02
Drugs
retifanlimabcapecitabineoxaliplatin
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON52108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52108.